Anaplastic thyroid cancer represents one of the most challenging malignancies affecting the thyroid gland, characterized by rapid growth and aggressive behavior that sets it apart from other thyroid cancer types. While extremely rare, accounting for less than 2% of all thyroid cancer cases, it is responsible for a disproportionate number of thyroid cancer-related deaths, making urgent and comprehensive treatment approaches absolutely essential for patients facing this diagnosis.

Understanding Treatment Goals in Anaplastic Thyroid Cancer

When someone receives a diagnosis of anaplastic thyroid cancer, the treatment journey begins immediately because time is critical. Unlike many other cancers where doctors have time to carefully plan treatment over weeks, anaplastic thyroid cancer grows so quickly that treatment must start within days. The main goals of treating this aggressive disease include controlling the tumor’s rapid growth, relieving symptoms that can make breathing and swallowing difficult, preventing the cancer from spreading to other parts of the body, and improving the patient’s quality of life for as long as possible.^[1]

Treatment decisions depend heavily on several important factors. The extent of the disease at diagnosis matters greatly, as does whether the tumor can be safely removed through surgery. The patient’s overall health condition, age, and personal preferences also play crucial roles in determining which treatments make the most sense. Because anaplastic thyroid cancer is always classified as stage IV disease due to its aggressive nature, treatment teams must consider whether the cancer is confined to the thyroid gland, has spread to nearby structures in the neck, or has already reached distant organs like the lungs, bones, or brain.^[11]

Modern medicine offers both standard treatments that have been used for years and newer experimental therapies being tested in clinical trials. Standard approaches include surgery, radiation therapy (treatment using high-energy rays), and chemotherapy (drugs that kill cancer cells). Emerging treatments involve targeted drugs that attack specific genetic changes within cancer cells and immunotherapy medications that help the body’s immune system fight cancer. A multidisciplinary team of specialists—including surgeons, medical oncologists who specialize in chemotherapy, radiation oncologists, endocrinologists, and palliative care experts—work together to create the best treatment plan for each individual patient.^[3]

Standard Treatment Approaches for Anaplastic Thyroid Cancer

Surgical Treatment

Surgery represents the most effective treatment when the tumor can be completely removed, but unfortunately, this is only possible in a minority of cases. By the time most patients are diagnosed, the tumor has grown so large or invaded surrounding structures so extensively that complete surgical removal would be too dangerous or impossible. When surgery is performed, the most common procedure is called debulking surgery, which means removing as much of the tumor as surgeons can safely take out, especially any portions threatening the patient’s ability to breathe.^[1]

The surgeon’s main priority during the operation is securing the airway to ensure the patient can breathe properly after surgery. Sometimes this requires placing a tracheostomy, which is a breathing tube inserted through an opening in the front of the neck below the tumor. The surgical team must also ensure the patient can receive nutrition, which sometimes means placing a feeding tube directly into the stomach if swallowing becomes too difficult or dangerous. Even when complete removal isn’t possible, surgery can provide significant symptom relief by reducing pressure on the windpipe, esophagus, and blood vessels in the neck.^[5]

Many factors determine whether surgery is advisable, including the tumor’s size, location, and how much it has invaded nearby critical structures like the trachea (windpipe), esophagus (food pipe), major blood vessels, and nerves controlling the vocal cords. Experienced thyroid cancer surgeons with specific expertise in anaplastic cases are essential because the surgery is complex and requires specialized skills. Unfortunately, when the cancer has already spread to distant organs at diagnosis—which happens in about 50% of cases—surgery on the neck tumor may not provide much benefit.^[4]

Radiation Therapy

Radiation therapy plays a crucial role in treating anaplastic thyroid cancer, even though these cancer cells are somewhat resistant to radiation compared to other cancer types. External beam radiation therapy directs high-energy rays from a machine outside the body toward the tumor to kill cancer cells. The current standard approach uses advanced techniques called intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiation therapy (3DRT), which allow doctors to target the tumor more precisely while protecting surrounding healthy tissues.^[12]

The typical radiation treatment course involves daily sessions, five days per week, for several weeks. The total radiation dose usually ranges from 50 to 60 Gray units, delivered in small daily portions to minimize damage to normal tissues. Some treatment centers use a technique called hyperfractionation, which means giving smaller doses of radiation twice daily instead of once. This approach may allow doctors to deliver higher total doses with fewer side effects, potentially improving local control of the tumor.^[14]

Radiation therapy can cause various side effects, especially in the neck area where treatment is focused. Common problems include skin redness and soreness similar to sunburn, difficulty swallowing that may worsen temporarily, increased fatigue, dry mouth, changes in taste, and hoarseness. These side effects typically develop gradually during treatment and may continue for several weeks after therapy ends. Some effects, such as damage to the salivary glands causing permanent dry mouth, can be long-lasting. The radiation oncology team works closely with patients to manage these side effects and maintain quality of life during treatment.^[1]

Chemotherapy

Chemotherapy uses powerful drugs that circulate throughout the body to kill rapidly dividing cancer cells. For anaplastic thyroid cancer, chemotherapy is often given at the same time as radiation therapy, a combination approach called chemoradiation, which may work better than either treatment alone. The chemotherapy drugs most commonly used include doxorubicin (also known by the brand name Adriamycin) and cisplatin, either used together or individually. Another group of drugs called taxanes—including paclitaxel and docetaxel—also shows activity against anaplastic thyroid cancer.^[14]

Doxorubicin works by interfering with cancer cells’ ability to copy their DNA, which stops them from dividing and growing. When used during radiation therapy, a low dose of doxorubicin (typically 15 mg per square meter of body surface area) is given weekly to enhance the radiation’s effectiveness. After radiation finishes, some patients continue receiving higher doses of doxorubicin every three weeks, but the total lifetime dose must be limited because this drug can damage the heart at cumulative doses above 550 mg per square meter.^[12]

Chemotherapy causes numerous side effects because it affects not only cancer cells but also normal rapidly dividing cells in the body. Common problems include nausea and vomiting, hair loss, fatigue, increased risk of infections due to low white blood cell counts, bleeding risks from low platelet counts, anemia from low red blood cell counts, mouth sores, and nerve damage in the hands and feet causing numbness or tingling. The medical team provides medications to prevent nausea, antibiotics if infections develop, and blood cell growth factors to help the bone marrow recover more quickly.^[12]

Innovative Treatments Being Tested in Clinical Trials

Targeted Therapy Based on Genetic Mutations

One of the most important advances in treating anaplastic thyroid cancer involves understanding the genetic changes that drive cancer cell growth. Scientists have discovered that many anaplastic thyroid cancers contain specific mutations in genes that control cell division and survival. By identifying these mutations through specialized testing, doctors can sometimes match patients with targeted drugs designed to block those particular abnormal proteins.^[8]

The most significant breakthrough involves a mutation called BRAF V600E, which is found in approximately 20-45% of anaplastic thyroid cancer cases. In 2018, the United States Food and Drug Administration approved a combination of two targeted drugs—dabrafenib and trametinib—specifically for patients with this mutation who have locally advanced or metastatic disease and no satisfactory surgery or radiation options. Dabrafenib blocks the abnormal BRAF protein directly, while trametinib blocks a protein called MEK that works downstream in the same cancer-promoting pathway.^[12]

Clinical trial results for this combination were remarkable compared to what was previously possible. In a study called the ROAR trial involving 23 evaluable anaplastic thyroid cancer patients with BRAF V600E mutations, 57% achieved a partial response meaning their tumors shrank significantly, and another 4% had complete responses where no tumor could be detected. Most impressively, 65% of responses lasted for six months or longer, giving patients meaningful periods of disease control. These drugs work by specifically targeting the cancer’s growth signals, which often makes them better tolerated than traditional chemotherapy, though they still cause side effects including fever, fatigue, skin rashes, joint pain, and occasionally more serious problems.^[12]

Before starting any targeted therapy, patients must undergo molecular testing of their tumor tissue. This specialized testing, sometimes called next-generation sequencing, looks for mutations not only in BRAF but also in many other cancer-related genes. Finding mutations in genes like RET, NTRK, or components of the PI3K/mTOR pathway can open additional treatment options with corresponding targeted drugs. The testing typically takes one to two weeks, and while waiting creates anxiety, it’s essential for selecting the most appropriate therapy.^[3]

Multi-Kinase Inhibitors

Another class of targeted drugs called multi-kinase inhibitors blocks multiple different proteins involved in cancer growth and blood vessel formation. Unlike the highly specific BRAF inhibitors, these drugs affect several pathways simultaneously, which may be beneficial since anaplastic thyroid cancers typically have numerous genetic abnormalities. Several multi-kinase inhibitors have shown promise in clinical trials for anaplastic thyroid cancer.^[15]

Lenvatinib is a multi-kinase inhibitor that blocks proteins called VEGF receptors (which promote blood vessel growth to tumors), FGFR receptors, RET, and KIT. In Japan, lenvatinib received approval for treating unresectable thyroid cancer including anaplastic cases, based on studies showing meaningful clinical activity. Patients take lenvatinib as a daily pill, and studies have found it can shrink tumors in some patients, though like all cancer drugs it also causes side effects. Common problems include high blood pressure, fatigue, decreased appetite, weight loss, diarrhea, and protein in the urine. The drug requires careful monitoring and sometimes dose adjustments to balance effectiveness against side effects.^[15]

Other multi-kinase inhibitors tested in anaplastic thyroid cancer include sorafenib, which blocks similar pathways to lenvatinib, and sunitinib, pazopanib, and vandetanib. While none of these drugs has become a standard treatment approved specifically for anaplastic thyroid cancer in the United States, they remain options for patients enrolled in clinical trials or in special circumstances when other treatments have failed. Research continues to determine which patients might benefit most from each drug and whether combining them with other treatments improves results.^[15]

Immunotherapy Approaches

Immunotherapy represents an exciting frontier in cancer treatment by helping the patient’s own immune system recognize and attack cancer cells. Some cancers manage to hide from immune surveillance by producing proteins like PD-L1 that essentially tell immune cells to leave them alone. Drugs called checkpoint inhibitors block these “don’t attack me” signals, unleashing immune cells to fight the cancer.^[6]

Research has shown that many anaplastic thyroid cancers produce high levels of PD-L1, suggesting they might respond to checkpoint inhibitor drugs targeting the PD-1/PD-L1 pathway. Clinical trials have tested drugs like pembrolizumab (Keytruda) and spartalizumab in anaplastic thyroid cancer patients. Early results showed that some patients experienced tumor shrinkage and disease stabilization, particularly those whose tumors tested positive for high PD-L1 expression. However, responses have been somewhat inconsistent, and research continues to identify which patients benefit most.^[15]

One promising approach combines immunotherapy with targeted therapy. A study published by researchers at MD Anderson Cancer Center found that combining the targeted drug dabrafenib plus trametinib with the immunotherapy drug pembrolizumab improved overall survival in patients with BRAF-mutated anaplastic thyroid cancer compared to historical outcomes with targeted therapy alone. This combination approach attacks the cancer through multiple mechanisms—blocking its growth signals directly while simultaneously enhancing immune recognition—potentially providing more durable disease control. However, combining treatments also increases side effect risks, requiring careful patient selection and monitoring.^[18]

Other Innovative Treatments in Clinical Trials

Scientists continue investigating numerous other treatment approaches for anaplastic thyroid cancer. Everolimus is a drug that blocks the mTOR protein, which is part of a pathway often abnormally activated in cancer cells. When genetic testing reveals mutations affecting the PI3K/mTOR pathway, everolimus may provide benefit. It works by interfering with cancer cells’ ability to grow and make new proteins they need for survival and division.^[15]

For tumors with RET gene fusion alterations, newer highly selective RET inhibitors like selpercatinib (Retevmo) show remarkable activity. Similarly, tumors with rare NTRK gene fusions may respond to drugs like larotrectinib (Vitrakvi) or entrectinib (Rozlytrek). These genetic alterations are uncommon in anaplastic thyroid cancer, occurring in only small percentages of cases, but when present, the corresponding targeted drugs can produce dramatic responses. This underscores why comprehensive genetic testing of the tumor is so valuable—it may identify a rare but highly treatable genetic change.^[14]

Researchers are also exploring combination strategies that attack cancer through multiple pathways simultaneously. Since anaplastic thyroid cancers typically harbor numerous genetic abnormalities, blocking just one pathway may not provide lasting control because the cancer finds alternate routes to keep growing. Clinical trials are testing combinations such as BRAF inhibitors plus MEK inhibitors plus immunotherapy, or multi-kinase inhibitors combined with chemotherapy. While these intensive approaches hold promise for better outcomes, they also raise concerns about increased toxicity and side effects that can affect quality of life.^[15]

Where Clinical Trials Are Conducted and Who Can Participate

Clinical trials for anaplastic thyroid cancer are conducted at major cancer centers throughout the United States, Europe, and other regions worldwide. Leading institutions like MD Anderson Cancer Center in Texas have established specialized clinics specifically for anaplastic thyroid cancer patients, bringing together experts who focus exclusively on this rare disease. These centers offer access to the newest experimental treatments and the most experienced medical teams.^[7]

Eligibility for clinical trials depends on numerous factors including the stage of disease, previous treatments received, overall health status, and specific characteristics of the tumor such as genetic mutations. Generally, trials accept patients whose cancer is not completely removable with surgery, has spread to distant sites, or has returned after initial treatment. Some trials specifically require certain genetic mutations like BRAF V600E, while others accept patients regardless of mutation status. Age requirements vary, but most trials accept adults over 18, and some have no upper age limit.^[3]

Patients interested in clinical trials should discuss this option with their oncology team as early as possible after diagnosis. Because anaplastic thyroid cancer progresses rapidly, enrollment cannot be delayed for long. The medical team can help search for appropriate trials, explain potential benefits and risks, and handle the enrollment process. Organizations like ThyCa: Thyroid Cancer Survivors’ Association maintain resources to help patients locate relevant clinical trials. Participating in a trial gives access to promising new treatments before they become widely available, and contributes to advancing knowledge that will help future patients.^[5]

Most common treatment methods

• Surgery
  • Debulking surgery to remove as much tumor as safely possible, particularly portions threatening the airway
  • Tracheostomy placement to secure breathing if tumor compresses the windpipe
  • Feeding tube placement when swallowing becomes difficult or dangerous
  • Complete surgical removal attempted when tumor is confined and resectable, though this is only possible in a minority of cases
• Radiation Therapy
  • Intensity-modulated radiation therapy (IMRT) to precisely target tumor while protecting healthy tissues
  • Three-dimensional conformal radiation therapy (3DRT) for accurate tumor targeting
  • Hyperfractionation approach with smaller doses given twice daily to potentially improve control
  • Typical total doses ranging from 50 to 60 Gray units delivered over several weeks
  • External beam radiation directed at the thyroid and neck area
• Chemotherapy
  • Doxorubicin (Adriamycin), often given at low weekly doses during radiation or higher doses every three weeks afterward
  • Cisplatin, used alone or combined with doxorubicin
  • Taxanes including paclitaxel and docetaxel
  • Chemoradiation combining chemotherapy with radiation therapy simultaneously
• Targeted Therapy
  • Dabrafenib plus trametinib combination for tumors with BRAF V600E mutations
  • Lenvatinib, a multi-kinase inhibitor approved in Japan for unresectable thyroid cancers
  • Sorafenib, another multi-kinase inhibitor targeting multiple cancer growth pathways
  • Selpercatinib (Retevmo) for tumors with RET gene alterations
  • Larotrectinib (Vitrakvi) or entrectinib (Rozlytrek) for rare NTRK gene fusions
  • Everolimus for tumors with PI3K/mTOR pathway mutations
• Immunotherapy
  • Pembrolizumab (Keytruda), a PD-1 checkpoint inhibitor
  • Spartalizumab, another PD-1 pathway blocker, particularly for PD-L1 positive tumors
  • Combination approaches pairing immunotherapy with targeted therapy drugs
• Palliative Care
  • Pain and symptom management throughout all stages of treatment
  • Nutritional support through feeding tubes when needed
  • Airway management including tracheostomy if breathing becomes compromised
  • Psychosocial and spiritual support for patients and families
  • Hospice care for patients declining life-prolonging treatments or when disease progresses despite therapy